ERBB2 and breast carcinoma: When chemotherapy is indicated in early HR-positive, HER2-negative breast cancer, 58% (48/82) and 21% (17/82) of participants preferred giving 6 and 8 cycles, respectively, while 21% (17/82) reported that the number of chemotherapy cycles does not matter.